
Xcelience, LLC
Advertisement
Articles by Xcelience, LLC


When the clinical protocol dictates and/or helps with patient compliance, it can be necessary for investigational drug products to be packaged in blinded blister cards (wallets) that contain two, or more, different strength products. The presence of different products (placebo and/or active strengths) inside a packaging suite clearly raises the potential for error. So to combat this, a whole series of physical segregation and process controls are put in place to act as safeguards against product mix-ups.
Advertisement
Latest Updated Articles
Clinical Blinded Blister Cards- How to Create Multi-Fill Blister Cards Using Product Placement Shields and UV Reactive InksPublished: March 23rd 2015 | Updated:
Considerations in the Development of Controlled Release FormulationsPublished: September 1st 2015 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
EMA Calls New EU Pharma Legislation Most Significant in Two Decades
2
FDA’s CNPV Pilot Gives First Approval to Antibiotic for Pneumonia and Sinusitis
3
FAQ: FDA’s Shifts in Pharma Regulation and Strategy in 2025
4
European Parliament Revamps Pharmaceutical Policy Framework
5
